GÖTTINGEN, Germany,
Nov. 26, 2021 /PRNewswire/ --
- The Group will expand its capacities for production,
innovation, and storage at its French facilities in Aubagne,
Cergy and Lourdes in order to meet the strong demand of the
biopharmaceutical industry
- The site in Aubagne, Sartorius' headquarters in France, will receive the major part of this
investment to build new cleanrooms and R&D laboratories
- Sartorius will create up to 400 new jobs on permanent
employment contracts between 2021 and 2025 at its four French
sites
A growth plan on an unprecedented scale
At the end of December 2020,
Sartorius employed almost 1,100 people on permanent contracts
in France across four different
sites in Aubagne, Cergy, Dourdan and Lourdes. By investing a total
of 100 million euros between 2021 and 2025, Sartorius plans to
expand and upgrade the Aubagne, Cergy and Lourdes facilities in the
following project activities:
- Create additional cleanroom space of 4,000 square meters
on top of the existing 5,000 square meters
- Deploy new R&D laboratories covering close to
2,000 square meters to strengthen the company's
innovation capacity
- Upgrade company logistics platforms and build over
10,000 square meters of warehouse facilities and
storage depots
- Digitalize and automate equipment to increase capacity and
competitive advantage
Agnès Pannier-Runacher, French Minister Delegate for Industry,
said: "With this development plan, Sartorius is a concrete example
of what we would like to see for our healthcare industry. Our goal
is to be able to produce strategic medical products and devices in
our country in the event of a crisis, yet also invest in the future
and be at the forefront of tomorrow's biotherapies. This is how we
will protect our citizens and make France the most innovative nation in
Europe in terms of the healthcare
industry."
This investment will enable the company to further boost
performance and become even more innovative as well as to meet the
growing demand of the market. In this context, Sartorius is
striving to accelerate and significantly expand the capacity of its
sites in France.
"We see our biopharmaceutical customers entering a new phase
characterized by a high pace of innovation, substantial investments
in their operations, and increasing demands on us as their
suppliers. We are supporting their efforts, significantly adding
capacity and increasing the speed of delivery," commented Luc
Burgard, Managing Director of Sartorius Stedim FMT and Head of
Operations of the Bioprocess Solutions Division at
Sartorius. "The investments in our French facilities will
strengthen our industrial capabilities in this country and secure
the long-term future of our operations here."
Sartorius in France plans to
create up to 400 new jobs between 2021 and 2025
To support its growth ambitions, Sartorius will create up to 400
new permanent-employment positions at the four French sites between
2021 and 2025. The Group plans to attract new talent in Operations,
such as production managers, machine operators, continuous
improvement managers; Product Development staff, including
engineers, data analysts; and Marketing personnel. Moreover,
Sartorius will support its teams in helping them acquire new,
cutting-edge skills, particularly in automation and digitalization
of the equipment they use in their workflows.
"Sartorius is making a strong commitment with this investment
and is bolstering its position as a leading partner of the
biopharmaceutical industry and life science research in
France," said Olivier Guitard, Managing Director of Sartorius
Stedim FMT and Head of Controlling of the Bioprocess Solutions
Division at Sartorius.
A profile of Sartorius
The Sartorius Group is a leading international partner of life
science research and the biopharmaceutical industry. With
innovative laboratory instruments and consumables, the Group's Lab
Products & Services Division concentrates on serving the needs
of laboratories performing research and quality control at pharma
and biopharma companies and those of academic research institutes.
The Bioprocess Solutions Division with its broad product portfolio
focusing on single-use solutions helps customers to manufacture
biotech medications and vaccines safely and efficiently. The Group
has been annually growing by double digits on average and has been
regularly expanding its portfolio by acquisitions of complementary
technologies. In fiscal 2020, the company earned sales revenue
of some 2.34 billion euros. At
the end of 2020, nearly 11,000 people were employed at the Group's
approximately 60 manufacturing and sales sites, serving customers
around the globe.
About Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of
the biopharmaceutical industry. As a total solutions provider, the
company helps its customers to manufacture biotech medications
safely, rapidly and economically. Headquartered in Aubagne,
France, Sartorius Stedim Biotech
is quoted on the Eurolist of Euronext Paris. With its own
manufacturing and R&D sites in Europe, North
America and Asia and an
international network of sales companies, Sartorius Stedim Biotech
has a global reach. The Group has been annually growing by double
digits on average and has been regularly expanding its portfolio by
acquisitions of complementary technologies. In 2020, the company
employed more than 7,500 people, and earned sales revenue of
1,910 million euros.
Follow Sartorius on Twitter @Sartorius_Group and
LinkedIn.
Logo -
https://mma.prnewswire.com/media/1696516/Sartorius_Logo.jpg
Press contact:
Agence RP by C&O
Océanne Trovo, oceanne.trovo@rpbyco.com, +33 (0)6 84 99
74 65
Coralie Jolly, coralie.jolly@rpbyco.com, +33 (0)6 85 91
09 38
View original
content:https://www.prnewswire.com/news-releases/sartorius-grows-operations-in-france-and-is-investing-100-million-euros-by-2025-301432432.html
SOURCE Sartorius AG
